3 results about "Hypromellose phthalate" patented technology

The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

This invention relates to the field of biopharmaceutical technology, and in particular to an antibody-targeted modified dual-strain prebiotic delivery system, its preparation method, and its applications. This invention modifies VCAM-1 antibody fragments onto *AKK* bacteria and *Bifidobacterium lactis* Probio-M8, then utilizes fructooligosaccharides and inulin as prebiotics to enhance probiotic metabolism and promote intestinal colonization. Finally, it coats the system with hydroxypropyl methylcellulose phthalate (HPMCP) enteric coating to construct the antibody-targeted modified dual-strain prebiotic delivery system—V-PM8-Am-FI-HPMC. The V-PM8-Am-FI-HPMC provided by this invention can simultaneously achieve intestinal flora regulation, lipid metabolism balance, inflammation suppression, ischemia improvement, and vascular anti-calcification, ultimately achieving the purpose of treating and / or improving atherosclerosis, while ensuring targeting and safety.